NCT04413253View on ClinicalTrials.gov

Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease

PHASE4TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

April 11, 2022

Study Completion Date

April 11, 2022

Conditions
Dry Eye Syndromes
Interventions
DRUG

Lifitegrast 5% Ophthalmic Solution

To reduce signs and symptoms of dry eye disease

DRUG

Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution

To determine the outcomes of reduction of signs and symptoms of dry eye disease with DEXTENZA as an added therapy, in addition to Xiidra therapy.

Trial Locations (1)

46040

Eye Surgeons of Indiana, Indianapolis

Sponsors

Collaborators (1)

Ocular Therapeutix, Inc.
All Listed Sponsors
collaborator

Ocular Therapeutix, Inc.

INDUSTRY

lead

Eye Surgeons of Indiana

NETWORK

NCT04413253 - Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease | Biotech Hunter | Biotech Hunter